Tenax Therapeutics, Inc. (TENX) analyst actions
Rating and price-target actions on TENX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the TENX overview →
1 measured TENX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 | Press release | +19.58% | +98.34% |
Keep exploring
More TENX: earnings → · SEC filings → · TENX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xencor, Inc. (XNCR) | 285 | +0.09% | 52% |
| NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) | 283 | 0.00% | 42% |
| GEMPHIRE THERAPEUTICS INC COMMON (GEMP) | 282 | -1.00% | 30% |
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.